Cellulitis: Causes, Mimics, Severity and Red Flags
Updated
Cellulitis is a bacterial infection of the deep dermis and subcutaneous tissue that causes spreading redness, warmth, swelling and tenderness, most often on one lower leg. Streptococci and Staphylococcus aureus cause most cases, though the organism is rarely identified. It is common, with an estimated 14.5 million cases a year in the United States, and often over-diagnosed, because stasis dermatitis, deep vein thrombosis and gout can look the same and red legs on both sides are rarely infected. This guide covers how cellulitis differs from erysipelas and an abscess, the bacteria and risk factors, the classic leg presentation and its mimics, how IDSA 2014 and the Eron classes grade severity, the red flags for necrotising fasciitis and sepsis, and how treatment is chosen, by name only.
- WhereDeep dermis and subcutaneous fat, most often on one lower leg
- Usual bacteriaStreptococci, often group A, and Staphylococcus aureus
- Common mimicsStasis dermatitis, DVT, gout, eczema, insect bite reactions
- SeverityIDSA purulent or non-purulent, mild to severe; Eron classes I to IV
At the bedside, the hard part is rarely the definition. It is deciding whether a red leg is infection at all, how the guideline in use grades it, and which findings mean surgery. AskMed is a medical question app for doctors, nurses, pharmacists, medical students and researchers. It searches journals, clinical guidelines and drug labels first, then answers with a link after every claim. Ask AskMed how IDSA 2014 and NICE NG141 differ on swabs and blood cultures in uncomplicated leg cellulitis, and each point links to the recommendation it comes from.
Ask AskMed how IDSA and NICE approach cultures in cellulitis:
How is cellulitis different from erysipelas and an abscess?
Cellulitis, erysipelas and an abscess are skin infections told apart by depth and by pus. Cellulitis involves the deep dermis and subcutaneous tissue, as the 2016 JAMA review by Raff and Kroshinsky defines it, and presents with expanding redness, warmth, tenderness and swelling. Erysipelas is a more superficial form: the IDSA 2014 guideline on skin and soft tissue infections says it putatively has more clearly delineated borders, that some clinicians limit the term to infection of the upper dermis, and that in some European countries the two words are used as synonyms. NICE NG141 adds that erysipelas is often hard to tell apart from cellulitis in practice and may be more associated with streptococci, so NICE manages both the same way. An abscess is a different problem: IDSA says the term cellulitis is not appropriate for inflammation around a collection of pus, such as a furuncle, and treats purulent infections on a separate path in which incision and drainage is the key step.
The distinction changes management. Non-purulent cellulitis and erysipelas are treated with antibiotics aimed mainly at streptococci, while a purulent collection needs drainage first. Necrotising fasciitis lies deeper again, along the fascia, and is a surgical emergency covered in the red flags section below.
What causes cellulitis and who is at risk?
Cellulitis is caused mainly by streptococci and Staphylococcus aureus entering through a break in the skin, and the strongest risk factors are local problems of the leg such as lymphoedema, wounds and cracked toe webs. NICE NG141 names Streptococcus pyogenes and S. aureus as the main bacteria, with Streptococcus pneumoniae, Haemophilus influenzae, gram-negative bacilli and anaerobes as less common causes. The IDSA 2014 guideline says the vast majority of cases arise from streptococci, often group A, while S. aureus less often causes cellulitis and is typically linked to an open wound or penetrating trauma, including injection drug use sites. Proof is rarely available: Raff and Kroshinsky report that an organism is identified in only about 15% of cases, and IDSA says blood cultures are positive in 5% or fewer. IDSA therefore does not recommend routine blood cultures or swabs, and NICE suggests a swab only when the skin is broken after a penetrating injury, water exposure or an infection acquired outside the UK.
Risk factors
The clearest data on risk factors come from a French case-control study of 167 people admitted with erysipelas of the leg and 294 controls (Dupuy and colleagues, BMJ, 1999). After adjustment, lymphoedema (odds ratio 71.2), a break in the skin barrier such as a leg ulcer, wound, fissured toe-web intertrigo, pressure ulcer or leg dermatosis (23.8), venous insufficiency (2.9), leg oedema (2.5) and being overweight (2.0) were each linked to infection, while diabetes, alcohol and smoking were not. Toe-web intertrigo accounted for an estimated 61% of cases at population level, which is why IDSA asks clinicians to examine the toe spaces in lower-limb cellulitis; the guide to athlete's foot covers that link.
The NHS adds previous cellulitis, poor circulation, difficulty moving around, a weakened immune system, lymphoedema, injecting drugs and surgical wounds. The CDC lists chickenpox, shingles, eczema, athlete's foot, cuts, ulcers, bites, tattoos and piercings, being overweight and chronic swelling of a limb, including after coronary artery bypass grafting. NICE notes that leg oedema can be an adverse effect of medicines such as calcium channel blockers, and asks prescribers to manage diabetes, venous insufficiency, eczema and oedema as part of treatment.
What does cellulitis of the leg look like?
Cellulitis of the leg classically appears as one warm, swollen, tender area of redness on a single lower leg that spreads over hours to days, sometimes with fever, chills or tender lymph nodes. The NHS says cellulitis can occur anywhere but is most common on the lower legs, and describes skin that is painful, hot and swollen, sometimes blistered, with flu-like symptoms and swollen, painful glands. The CDC adds that the skin may look pitted, like orange peel. A 2022 review of bilateral leg cellulitis by Chuang and colleagues calls it a well-known fact that cellulitis is most often unilateral. Redness is harder to judge on darker skin: both the NHS and NICE NG141 warn that it may be less visible on brown or black skin, so warmth, swelling, tenderness and the history of spread carry more weight there. There is often an entry point, such as a cut, ulcer or cracked toe web, but the NHS notes the break may be too small to notice.
- Mark the edge: NICE suggests drawing around the infection with a single-use surgical marker pen before treatment to track progress, and accepts that some early spread beyond the line may occur.
- Look for the way in: check the toe webs, ulcers, wounds, bites and areas of eczema, and look for lymphoedema or chronic oedema behind it.
- Check the whole patient: fever, a fast pulse or breathing, low blood pressure and confusion move the case up the severity scales described below.
- Expect a slow fade: the NHS says symptoms may get worse in the first 48 hours of antibiotics, and NICE says the skin takes some time to return to normal after the course ends.
What conditions mimic cellulitis?
The conditions that most often mimic cellulitis are stasis dermatitis, deep vein thrombosis, gout, eczema and allergic dermatitis, superficial thrombophlebitis and inflammatory reactions to insect bites or immunisations, and NICE NG141 asks prescribers to exclude other causes of redness before treating. Misdiagnosis is common. In a study of 259 patients admitted from the emergency department of a large US urban hospital with lower-limb cellulitis, Weng and colleagues (JAMA Dermatology, 2017) found that 79, or 30.5%, had another condition, often called pseudocellulitis. Of the 52 misdiagnosed patients admitted mainly for cellulitis, 44 did not need hospital care and 48 received antibiotics they did not need, and the authors estimated 50,000 to 130,000 unnecessary admissions a year in the United States. Laterality is a strong clue: Chuang and colleagues found only 13 reported cases of definite bilateral lower-limb cellulitis since 1990, and name stasis dermatitis as the condition most often misdiagnosed as cellulitis, especially when both legs are involved.
- Stasis dermatitis: usually both legs, on a background of venous insufficiency; Chuang and colleagues note it can also become secondarily infected, so the two can coexist.
- Deep vein thrombosis: NICE lists it among the diagnoses to consider when a red, swollen leg is reassessed; the Wells score for DVT gives a pre-test probability before D-dimer or ultrasound.
- Gout: inflammation centred on a joint; Chuang and colleagues note that gouty arthritis can mimic bilateral cellulitis when several joints are involved. See the guide to gout.
- Haematoma: often with a history of anticoagulant use or trauma, according to the same review.
- Others on the NICE list: eczema, allergic dermatitis, superficial thrombophlebitis and reactions to insect bites or immunisations.
None of these rules cellulitis out on its own, and an infection can sit on top of chronic skin disease. The differential is where a cited answer saves time. Ask AskMed which findings favour stasis dermatitis over cellulitis in a patient with bilateral red lower legs, or what NICE NG141 asks clinicians to exclude before starting antibiotics, and the answer links the guideline wording and the pseudocellulitis studies behind each point.
Ask AskMed what separates cellulitis from its mimics:
How is cellulitis severity classified?
Cellulitis severity is classified in two main ways: the IDSA 2014 guideline splits skin infections into purulent and non-purulent and grades each as mild, moderate or severe, while the Eron classification, which NICE NG141 names as a severity tool used in practice, sorts patients into classes I to IV. In the IDSA algorithm, typical cellulitis or erysipelas with no focus of pus is non-purulent. It is mild without systemic signs and moderate with systemic signs of infection. It is severe in patients who have failed oral antibiotics, who are immunocompromised, or who show signs of deeper infection such as bullae, skin sloughing, hypotension or organ dysfunction. IDSA judges systemic signs with the systemic inflammatory response syndrome criteria, which include a temperature above 38°C or below 36°C, a respiratory rate above 24 breaths per minute and a heart rate above 90 beats per minute. Purulent infections, such as abscesses, follow their own mild, moderate and severe steps, starting with incision and drainage.
- Class I: afebrile and healthy apart from the cellulitis.
- Class II: febrile and ill-appearing but with no unstable comorbidity, or systemically well with a comorbidity such as peripheral vascular disease, chronic venous insufficiency or morbid obesity.
- Class III: toxic appearance, at least one unstable comorbidity, or a limb-threatening infection.
- Class IV: sepsis syndrome or a life-threatening infection, such as necrotising fasciitis.
NICE NG141 does not adopt a single score. Its committee noted that severity tools such as the Eron classification and the Dundee classification of Koerner and Johnson are used in practice but have not been tested in randomised trials, so it framed its advice around oral versus intravenous treatment in a way that fits those tools. Alongside severity, NICE weighs the site of infection, with the area around the eyes and nose of more concern, the risk of uncommon organisms, any previous swab results and the person's MRSA status. In the trial protocol by Quirke and colleagues, for example, Eron class I and II cellulitis was the group considered treatable with oral antibiotics as an outpatient.
Grading is where the guidelines differ most, and where a sourced answer helps on a ward round or in an exam. Ask AskMed how an Eron class II patient with chronic venous insufficiency maps onto the IDSA mild, moderate and severe categories, or which features make NICE NG141 consider hospital referral, and every step of the answer links to the guideline text.
Ask AskMed how a cellulitis presentation is graded:
When is cellulitis an emergency?
Cellulitis becomes an emergency when there are signs of necrotising fasciitis, sepsis or spread to deeper structures such as bone, joint or the orbit, and NICE NG141 says these people should be referred to hospital. The classic warning sign of necrotising fasciitis is severe pain that seems out of proportion to what the skin shows. The IDSA 2014 guideline adds a hard, wooden feel of the subcutaneous tissue, bullae, skin discolouration or gangrene, loss of sensation, crepitus from gas in the tissues and systemic toxicity, often with altered mental status. The CDC lists decreased sensation, bullae, crepitation, profound pain and skin necrosis as red flags, warns that early signs can be hard to tell from cellulitis, and says imaging may help but should never delay surgical exploration. Treatment is urgent surgical debridement with broad-spectrum intravenous antibiotics, and the CDC puts recent mortality from streptococcal necrotising fasciitis at around 15 to 20%, rising with age and with streptococcal toxic shock syndrome.
- Refer to hospital (NICE): signs suggesting orbital cellulitis, osteomyelitis, septic arthritis, necrotising fasciitis or sepsis.
- Consider referral or specialist advice (NICE): severely unwell; infection near the eyes or nose, including periorbital cellulitis; possible uncommon organisms after a penetrating injury, water exposure or infection acquired abroad; spreading infection not responding to oral antibiotics; lymphangitis; or unable to take oral antibiotics.
- Admit (IDSA): concern for a deeper or necrotising infection, poor adherence, severe immunocompromise, or failing outpatient treatment.
- Reassess (NICE): symptoms worsening rapidly, no improvement within 2 to 3 days, the person becoming systemically very unwell, pain out of proportion, or redness spreading beyond the first presentation.
Sepsis tools help structure the systemic check: the qSOFA calculator and the NEWS2 calculator turn vital signs and mental state into a score. NICE also notes that children under 1 year and people who are frail or have diabetes or immunosuppression are at higher risk of complications. For patients reading this, the NHS advises an urgent GP appointment or NHS 111 for skin that is painful, hot and swollen, and calling 999 or going to A&E if it comes with a very high temperature, a fast heartbeat or breathing, purple patches on the skin, dizziness or fainting, confusion, or cold, clammy or pale skin.
How is cellulitis treated?
Cellulitis is treated with an antibiotic chosen for the likely organism, the severity and the site, together with elevation of the limb and care of whatever let the bacteria in; this guide names treatments only and gives no doses or course lengths. NICE NG141 recommends offering an antibiotic, by mouth first line when the person can take oral medicines and is not severely unwell, and names flucloxacillin as the first choice because it covers both Streptococcus pyogenes and S. aureus. For penicillin allergy, or when flucloxacillin is unsuitable, NICE lists clarithromycin, erythromycin in pregnancy, or doxycycline. For infection near the eyes or nose it prefers co-amoxiclav, with specialist advice. Its alternatives for severe infection are co-amoxiclav, cefuroxime, clindamycin and ceftriaxone, and it adds vancomycin, teicoplanin or linezolid when MRSA is suspected or confirmed. NICE found that routinely combining two antibiotics gave no benefit over one and carries more adverse effects and resistance risk.
The IDSA 2014 guideline asks for an agent active against streptococci in typical non-purulent cellulitis without systemic signs. It recommends an antibiotic that also covers MRSA when cellulitis follows penetrating trauma, or comes with MRSA infection elsewhere, nasal MRSA colonisation, injection drug use or systemic inflammatory response syndrome, and calls vancomycin plus piperacillin-tazobactam or a carbapenem (imipenem or meropenem) a reasonable empiric regimen for severe infection, with prompt surgical consultation when necrotising infection is possible. Purulent infections are drained. In US practice, oral beta-lactams that cover streptococci and meticillin-sensitive S. aureus include cephalexin, whose FDA label covers skin infections caused by both organisms; Raff and Kroshinsky note that failure to improve should prompt a search for resistant organisms, a mimic or an underlying condition.
Recovery and recurrence
Both guidelines pair antibiotics with elevation of the affected limb and treatment of predisposing factors, and IDSA names oedema, obesity, eczema, venous insufficiency and toe-web abnormalities. Recurrence is common: IDSA reports annual recurrence rates of about 8% to 20% after an episode, especially in the legs. NICE does not routinely offer antibiotic prophylaxis, but specialists may consider a trial for adults treated in hospital or under specialist advice for at least 2 separate episodes in the previous 12 months, using phenoxymethylpenicillin, or erythromycin in penicillin allergy, and reviewing it at least every 6 months. IDSA suggests considering prophylaxis for people with 3 to 4 episodes a year despite efforts to control predisposing factors.
Frequently asked questions
Is cellulitis contagious?
No. The NHS says cellulitis cannot be caught from another person, and the CDC says people generally cannot catch it from others. The bacteria usually enter through a break in the person's own skin, such as a cut, bite, ulcer or cracked toe web.
What is the difference between cellulitis and erysipelas?
Erysipelas is a more superficial infection of the upper dermis with sharper borders, while cellulitis reaches the deep dermis and subcutaneous fat. IDSA notes that some European countries use the terms as synonyms, and NICE NG141 manages both the same way.
Can cellulitis affect both legs at once?
Rarely. A 2022 review found only 13 reported cases of definite bilateral lower-limb cellulitis since 1990. Redness in both legs is much more often stasis dermatitis or another mimic, which is why bilateral red legs call for a careful look before antibiotics.
Why can the redness spread after antibiotics start?
NICE NG141 accepts that some early spread beyond a marked edge may occur, and the NHS says symptoms may worsen in the first 48 hours. NICE advises reassessment if symptoms worsen rapidly or significantly, or do not start to improve within 2 to 3 days.
Are blood cultures needed in cellulitis?
Not routinely. IDSA 2014 says blood cultures are positive in 5% or fewer cases and recommends them for patients with malignancy on chemotherapy, neutropenia or severe immunodeficiency. NICE suggests a skin swab only when the skin is broken and an unusual organism is possible.
Can cellulitis come back?
Yes. IDSA reports annual recurrence rates of about 8% to 20% after a previous episode, especially in the legs. Treating oedema, lymphoedema, eczema, venous insufficiency and toe-web problems lowers the risk, and specialists may consider antibiotic prophylaxis after repeated episodes.
Sources
- National Institute for Health and Care Excellence. Cellulitis and erysipelas: antimicrobial prescribing (NG141), recommendations and summary of the evidence. NICE guideline, 27 September 2019.
- Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52.
- Quirke M, Wakai A, Gilligan P, O'Sullivan R. Oral flucloxacillin and phenoxymethylpenicillin versus flucloxacillin alone for the emergency department outpatient treatment of cellulitis: study protocol for a randomised controlled trial. Trials. 2013;14:164. Table 1 reproduces the classification of Eron LJ, et al. J Antimicrob Chemother. 2003;52 Suppl 1:i3-i17.
- Raff AB, Kroshinsky D. Cellulitis: a review. JAMA. 2016;316(3):325-337.
- Dupuy A, Benchikhi H, Roujeau JC, et al. Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ. 1999;318(7198):1591-1594.
- Weng QY, Raff AB, Cohen JM, et al. Costs and consequences associated with misdiagnosed lower extremity cellulitis. JAMA Dermatol. 2017;153(2):141-146.
- Chuang YC, Liu PY, Lai KL, Tseng CH. Bilateral lower limbs cellulitis: a narrative review of an overlooked clinical dilemma. Int J Gen Med. 2022;15:5567-5578.
- Centers for Disease Control and Prevention. About cellulitis and Clinical guidance for necrotizing fasciitis. 5 August 2025.
- NHS. Cellulitis, last reviewed 18 April 2024, and Necrotising fasciitis, last reviewed 2 February 2026.
